HealthcareMid capRs 11,483 crRs 19.2 cr traded a day
Close on 2026-08-21
750.00
−0.39%
52-week range97% of the way up
414.05760.95
Market cap
11,483 cr
P/E (TTM)
39.2×
industry 44×
EPS (TTM)
19.12
Revenue YoY
+13.9%
Q1 FY27
Profit YoY
+56.1%
Net margin
8.7%
+2.3pt vs a year ago
Growth trend
+4.2pt
vs last quarter’s YoY
1 month
+7.8%
Below 52w high
1.5%
RSI (14)
69
Daily swing
3.8%
average true range
Volume
0.7×
vs 20-day average
Traded
Rs 19 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
1 week
+3.22%
1 month
+7.77%
3 months
+40.92%
6 months
+55.52%
1 year
+58.66%
The read
written from the numbers on this page
The evidence leans constructive8 supporting, 0 against, 0 worth knowing
Supporting
trading 42% above its 200-day average
sitting at 97% of its 52-week range, with little overhead supply from trapped buyers
up 59% over twelve months
matches closing in on a 52-week high, which has beaten the market by +0.51 points over 20 sessions across 27,282 past signals
2 of the scans it matches have a positive measured record
5 independent kinds of evidence agree today, which is uncommon
revenue grew 14% year on year in the quarter ending 2026-06-30
net margin has widened from 4.2% to 8.7% across four quarters
Against
nothing the data supports either way
Worth knowing
nothing the data supports either way
What would change this read: a close below 528, its 200-day average; a failure to hold the top of its 52-week range.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
read from the filings, with the figure behind every line
Working3
Net profit +56.1% year on year, Rs 65 cr to Rs 101 cr.
+56.1%Rs 65 crRs 101 cr
Profit grew faster than revenue, +56.1% against +13.9%.
+56.1%+13.9%
Net margin moved from 6.3% to 8.7%.
6.3%8.7%
Needs watching
Nothing in the filings stands out either way.
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.
How it has performed
price return over each window, measured against zero
What the scans say today
10 of 47 matched on 2026-08-21
AKUMS matches 10 of the 47 scans today, across 5 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
AKUMS trades at 39× trailing earnings, above its median of 23× over this window — 71% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352) · Results filings were typically -0.52pt vs the market over the next 5 sessions (n=7,520) · Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 14% against the same quarter a year earlier
profit rose 56% year on year
net margin widened from 7.0% to 8.7%
Going against it
nothing clear in the filed numbers
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
1,167
139
101
6.53
8.7%
Q4 FY26
2026-03-31 · consolidated
1,158
121
81
5.53
7.0%
Q3 FY26
2025-12-31 · consolidated
1,160
100
68
4.33
5.8%
Q2 FY26
2025-09-30 · consolidated
1,018
66
43
2.66
4.2%
Q1 FY26
2025-06-30 · consolidated
1,024
96
65
4.15
6.3%
Q4 FY25
2025-03-31 · consolidated
1,056
75
150
9.64
14.2%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+11.8%
Versus 200-day average+42.1%
Below 52-week high-1.4%
Above 52-week low+81.1%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)68.6
Higher closes in last 53 of 5
Six-month return+55.52%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.77%
Volume versus 20-day0.7x
Median daily turnoverRs 19.2 cr
Peers
Healthcare · 67 classified companies
AKUMS trades at 39.2× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — priced roughly in line with them. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.